Blockchain Registration Transaction Record

Watchdog Warns Psychiatry May Undermine Antidepressant Deprescribing Plan

CCHR warns psychiatry may undermine HHS antidepressant deprescribing plan. Learn about risks, withdrawal, and informed consent safeguards.

This news matters because it highlights a critical tension between patient safety and the financial interests of psychiatry and pharmaceutical companies. With antidepressant overprescribing and withdrawal risks routinely minimized, the HHS plan could be a vital step toward safer mental health care. However, if psychiatry successfully weakens these protections, patients may continue to face harm from unnecessary or prolonged antidepressant use, including severe withdrawal effects like brain zaps and cognitive impairment. Understanding this conflict empowers patients and advocates to demand stronger informed consent and deprescribing support, potentially saving lives and improving outcomes.